Saffron for Premenstrual Syndrome

Verdict: Promising but preliminary for PMS relief

Early evidence suggests that a standardized saffron extract (commonly 30 mg/day) may modestly ease premenstrual symptoms, but the trial base is still thin and major health authorities have not endorsed it for PMS.

B 🟡 B Preliminary Evidence Published with Warning

🔬Why this grade7-layer evidence engine

The evidence points in a consistent direction. A 2026 systematic review and meta-analysis (PMID 41151539) found saffron significantly reduced PMS symptom severity versus placebo (SMD -0.64, 95% CI -0.84 to -0.44), with a smaller effect on menstrual pain. A 2020 randomized trial in 120 women with PMDD (PMID 33457343) found 30 mg/day saffron beat placebo on the DRSP symptom diary (P=0.027) and matched fluoxetine while causing fewer side effects. Three broader reviews (PMIDs 36249453, 38558480, 38694315) reach similarly favorable but non-quantitative conclusions.

The grade stays at preliminary rather than strong because the dedicated trial base is small: essentially one direct PMS/PMDD RCT (n=120, single-center, two cycles) plus one PMS-specific meta-analysis. Heterogeneity and total sample size are not fully reported, and a single negative trial could shift the picture.

Institutional backing is also limited. Cleveland Clinic notes small studies suggest saffron could improve PMS-related depression, but Mayo Clinic, Harvard Health, NIH, and the American College of Obstetricians and Gynecologists do not list it for PMS. The FDA treats saffron only as a food flavoring, and EFSA rejected related mood claims, stating 'a cause and effect relationship has not been established.' Saffron is best seen as an optional adjunct, not a first-line treatment; pregnant or trying-to-conceive women should avoid it.

⚖️

Scoring transparency

All scores computed by a 7-layer evidence engine — fully auditable
Raw score 0.69
D
C
B
A
S
← counter-evidence / ineffectiveeffective / strong evidence →
Final grade
B · Published with Warning
Confidence
82%
Highly consistent evidence
Evidence level
E2
Multiple high-quality MAs (≥2 independent, consistent)

How strongly each layer supports this effect

lower = less supportive
L1 ExamineGlobal benchmark
0.50
L5 Clinical bodiesAuthoritative stance
0.62
L3 MechanismPlausibility
0.65
L11 AI re-checkIndependent read
0.65
L2 PubMedPrimary literature
0.85
Against Mixed Supports
View the full decision path (audit trail)
  1. compute_raw_score — 加權公式: L2×0.30 + L3×0.25 + L5×0.25 + L11×0.10 + L1×0.10 = 0.687
  2. tier_from_score — 依分數區間映射至 tier letter
  3. apply_hec_rules — 高品質 SR/MA 顯示 positive (1 篇 > 0 negative)
  4. tier_strict_requirement_check — Tier 條件達標,未降階
  5. detect_disputes — 偵測到 0 個 hard + 0 個 soft dispute
  6. decide_status — 依 tier + dispute 結果決定 status

📄PubMed studies (5)L2 · primary research & systematic reviews

Effect of saffron on premenstrual syndrome and dysmenorrhea: a systematic review and meta-analysis
PMID: 41151539 2026 統合分析
Finding: Saffron significantly reduced PMS symptom severity vs placebo (SMD -0.64, 95% CI -0.84 to -0.44) and dysmenorrhea severity (SMD -0.51, 95% CI -1.01 to -0.01). Random-effects model via Comprehensive Meta-Analysis software; databases searched: PubMed, Web of Science, Science Direct; Cochrane risk-of-bias tool used.
Effect size: [object Object]
View on PubMed
Saffron for the Management of Premenstrual Dysphoric Disorder: A Randomized Controlled Trial
PMID: 33457343 2020 隨機對照試驗 n = 120
Finding: All three arms (saffron, fluoxetine 20 mg BID, placebo) showed significant within-group improvement (P<0.001). Saffron showed significant superiority to placebo on DRSP (P=0.027). No significant between-group difference on Hamilton scores (P>0.05). Fluoxetine had significantly higher adverse-effect rate (P=0.01); saffron was well tolerated.
View on PubMed
The neuropsychotropic effects of Crocus sativus L. (saffron): an overview of systematic reviews and meta-analyses investigating its clinical efficacy in psychiatric and neurological disorders
PMID: 36249453 2022 系統性回顧
Finding: Concluded saffron is 'beneficial, safe, and tolerable' for various conditions including PMS; called for further high-quality, large-scale studies. PMS-specific pooled effect sizes not reported in this overview.
🟠 Limited quality
View on PubMed
Therapeutic effects of saffron (Crocus sativus L) on female reproductive system disorders: A systematic review
PMID: 38558480 2024 系統性回顧
Finding: Across 50 studies the review concluded saffron 'can improve the symptoms of several female reproductive system disorders' attributed to crocin, crocetin, and safranal. Cited Agha-Hosseini et al. (2008) double-blind placebo-controlled RCT specifically on PMS. No new pooled PMS effect sizes computed.
View on PubMed
Saffron extract as an emerging novel therapeutic option in reproductive and sexual health: a literature review
PMID: 38694315 2024 Other
Finding: Identified saffron (Crocus sativus) as a promising therapeutic agent for reproductive/sexual health conditions including PMS; lacks pooled quantitative analysis.
🟠 Limited quality
View on PubMed

🏛️Regulatory & authoritative positionsL4/L5 · FDA / EMA / NIH ODS / Cochrane / Mayo …

L4a US FDA
Cautious
Saffron (Crocus sativus L.); CAS 977051-90-3; 21 CFR 73.500, 182.10; COLOR OR COLORING ADJUNCT, FLAVOR ENHANCER, FLAVORING AGENT OR ADJUVANT. source↗
L4b EU EFSA
Against
a cause and effect relationship has not been established source↗
L4d TW TFDA / 衛福部
Cautious
番紅花(Crocus sativus L.)之柱頭可供食品使用 source↗
L5c Cleveland Clinic
Supportive
Some small research studies have found that saffron could improve PMS-related depression. source↗
PMID 100% verifiedevery citation checked via NCBI Entrez
🔬5 PubMed studiesindependently re-checked by multiple sub-agents
engine_version: v1.0 claim_id: CLM-COND-pms-INT-saffron-001 繁體中文版 →